On January 1, 2018, the final rule went into effect amending 49 CFR Part 40. The DOT announced several revisions, most notably the addition of hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel, as well as methylenedioxyamphetamine as an initial test analyte. The final rule also removed methylenedioxyethylamphetamine as a confirmatory test analyte.
